Related Experiment Videos

Phase II trial design considerations for small-cell lung cancer

T D Moore¹, E L Korn

¹Clinical Investigations Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Journal of the National Cancer Institute

|February 5, 1992

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity.

ESMO open·2020

Interim monitoring for non-inferiority trials: minimizing patient exposure to inferior therapies.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Assessing treatment efficacy in the subset of responders in a randomized clinical trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2015

Evaluation of chemoresponse assays as predictive markers.

British journal of cancer·2015

Assessing causal relationships between treatments and clinical outcomes: always read the fine print.

Bone marrow transplantation·2011

See all related articles